Introduction

Biopharma SHAKTI is a flagship scheme announced in the Union Budget 2026–27 to strengthen India’s domestic capacity in biologics and biosimilars. The scheme aims to move India beyond its traditional strength in generic medicines and build a globally competitive ecosystem for high-value biopharmaceutical innovation, manufacturing, testing, and regulation.

The scheme has been introduced in response to major structural needs in India’s health and pharmaceutical sector.

Key reasons include:

• Rising burden of non-communicable diseases such as cancer, diabetes, and autoimmune disorders
• Need to reduce dependence on imported advanced biologic therapies
• Requirement to make biologics and biosimilars more affordable
• Shift from animal testing to more accurate human-relevant testing systems
• Need to strengthen India’s global position in advanced pharmaceuticals
• Pressure from changing global trade conditions, including tariff concerns on pharmaceutical products

Financial outlay

• Total outlay – Rs 10,000 crore
• Duration – 5 years starting from financial year 2026–27

This large allocation shows that the scheme is intended as a full ecosystem-building mission rather than a limited subsidy program.

Main objective

The main objective of the scheme is to transform India from a major producer of generic drugs into a major global hub for advanced biologics and biosimilars.

It seeks to do this through:

• Research and innovation support
• Human-relevant testing methods
• Manufacturing ecosystem creation
• Clinical trial expansion
• Regulatory strengthening
• Institutional capacity building

Link with earlier policy framework

The scheme aligns with the National Biopharma Mission, 2017.

The National Biopharma Mission aimed to:

• Strengthen India’s biopharma ecosystem
• Promote indigenous product development
• Increase India’s role in the global biotech market
• Support industry-academia collaboration

Biopharma SHAKTI can be seen as a next-generation policy push focused specifically on advanced biopharmaceuticals and translational readiness.

Disease focus

The scheme prioritizes therapies for non-communicable diseases.

Main focus areas include:

• Cancer
• Diabetes
• Autoimmune disorders
• Other chronic high-burden diseases

This is important because non-communicable diseases account for a large share of mortality in India. The provided note states that they account for 63 percent of all deaths in India.

Core manufacturing shift

One of the most important features of the scheme is the move away from conventional animal-based testing and toward Non-Animal Methodologies.

This is significant because biologics are complex products that respond better to human-relevant testing models than traditional animal systems in many situations.

The scheme promotes:

• Organoids
• Organ-on-a-chip systems
• 3D bioprinting
• Advanced in silico models
• Ex vivo human tissue systems

Infrastructure and institutional support

The scheme includes major institutional expansion.

Important provisions:

• Establishment of 3 new National Institutes of Pharmaceutical Education and Research
• Upgradation of 7 existing NIPERs into centres of excellence for translational research
• Creation of a national network of more than 1,000 accredited clinical trial sites

This shows that the scheme is not limited to production incentives. It also aims to improve the full pipeline from research to trials to commercialization.

Regulatory reform

The scheme also seeks to strengthen regulation through reform of the Central Drugs Standard Control Organisation.

One key proposal is:

• Creation of a dedicated Scientific Review Cadre within CDSCO

This is intended to:

• Improve quality of regulatory review
• Reduce approval delays
• Align India’s approval timelines with international benchmarks
• Build scientific specialization in drug evaluation

Importance of biologics

Biologics are not ordinary chemically synthesized drugs. They are produced using living systems such as bacteria, yeast, or animal cells.

Examples include:

• Insulin
• Monoclonal antibodies
• Vaccines
• Gene therapies

They are far more complex than traditional small-molecule drugs because:

• They are much larger in size
• They have complex three-dimensional structures
• Their production process is highly sensitive
• Small manufacturing variations may affect quality and performance

What are biosimilars

Biosimilars are products that are highly similar to an already approved reference biologic.

Important features:

• They are not exact copies like ordinary generic drugs
• They must show no clinically meaningful difference in safety and efficacy
• They are generally cheaper than the original biologic
• They can significantly improve affordability and access

The provided content notes that biosimilars are usually 30 to 70 percent cheaper than the original biologic.

Why India needs a biologics push

India is already strong in generic medicines, but biologics represent the next high-value frontier.

Need for the shift:

• Higher therapeutic value
• Greater role in cancer and chronic disease treatment
• Larger global market opportunity
• Better export potential
• Reduced import dependence for complex therapies
• Strategic healthcare self-reliance

Non-Animal Methodologies

Non-Animal Methodologies, also called New Approach Methodologies, are scientific tools used to evaluate safety and efficacy without depending on traditional animal testing.

These methods aim to replace, reduce, or refine the use of animals in research.

Major technologies under NAMs

Organoids

Organoids are 3-dimensional mini-organs grown from human stem cells. They mimic the structure and biology of real human organs and are useful for disease modelling, drug screening, and personalized medicine.

Organ-on-a-chip

These are microfluidic devices lined with living human cells that simulate the physiological environment of specific organs. They can replicate functions such as breathing, blood flow, and tissue interaction.

3D bioprinting

This technique uses cells and supportive materials as bio-inks to print tissue structures layer by layer. It helps researchers study drug penetration, tissue response, and disease mechanisms.

In silico models

These are computer-based and AI-driven simulation systems that predict how molecules may behave in the human body. They support faster screening and reduce early-stage failures.

Ex vivo systems

These use living human tissues or organs outside the body for short-term testing. They generate more human-relevant data than many conventional animal models.

Advantages of NAMs

The scheme’s shift toward NAMs is based on both scientific and economic logic.

Major advantages:

• Better predictive accuracy for human biology
• Lower dependence on animal models
• Faster candidate screening
• Reduced development cost
• Better support for precision medicine
• Improved translational success from lab to clinic

The provided note mentions that NAMs may reduce drug development costs by 10 to 26 percent and shorten candidate identification time by nearly 20 percent.

Why NAMs matter in biologics

Biologics are especially sensitive to receptor interactions, immune responses, and human tissue behavior. Animal models may not always reflect these accurately.

NAMs are better suited because they:

• Use human-derived cells or tissues
• Better replicate patient-specific biology
• Improve safety prediction
• Help identify toxicity earlier
• Support personalized therapy development

Regulatory support for NAMs

A major policy support point is the formal recognition of NAMs in India’s regulatory framework.

Important legal development:

• New Drugs and Clinical Trials Amendment Rules, 2023 recognized NAMs as valid alternatives to animal data

This is very important for exam answers because it shows that Biopharma SHAKTI is supported by an emerging regulatory base rather than being only an aspirational budget announcement.

India’s pharmaceutical sector context

The scheme must be understood against the broader strength of India’s pharmaceutical sector.

Important facts from the provided content:

• India is the 3rd largest pharmaceutical producer by volume
• India is 11th by value
• India supplies 20 percent of global generic medicines
• It supplies a large share of global DPT, BCG, and measles vaccines
• Annual turnover reached Rs 4.72 lakh crore in FY25
• Over 10,500 manufacturing units operate in the sector
• Exports have grown at about 7 percent CAGR over the last decade

This shows that Biopharma SHAKTI is meant to build on an already strong base and upgrade India into the next stage of pharma leadership.

Link with medical technology

The scheme also fits into India’s broader health-industrial expansion, including med-tech.

The provided content notes that India now exports advanced medical devices such as:

• MRI scanners
• CT scanners
• Cardiac stents

to 187 countries.

This indicates a broader policy push toward high-value health technology manufacturing.

Significance of the scheme

For healthcare

• Improves access to affordable biologic therapies
• Supports treatment of cancer, diabetes, and chronic diseases
• Can reduce long-term import dependence
• Improves testing relevance and patient safety

For industry

• Encourages movement into high-value pharma segments
• Builds manufacturing and innovation capability
• Strengthens translational research infrastructure
• Improves competitiveness in global biopharma

For science and technology

• Promotes advanced drug development platforms
• Supports organoid and chip-based research
• Encourages interdisciplinary biomedical innovation
• Strengthens research-industry linkages

For regulation

• Moves toward science-based faster approvals
• Builds specialized review capacity
• Improves international credibility of Indian pharma regulation

Challenges

Despite its promise, implementation will face real challenges.

Key concerns:

• High cost and technical complexity of biologics manufacturing
• Need for trained interdisciplinary workforce
• Standardization of NAM platforms
• Regulatory validation of new testing systems
• Ensuring affordability and not just industrial growth
• Coordination between academia, regulators, and private industry
• Long gestation period for advanced biopharma innovation

Analytical understanding

Biopharma SHAKTI is not just a pharma production scheme. It represents a strategic transition in India’s health-industrial model.

The deeper shift is:

• from generics to biologics
• from volume to value
• from animal testing to human-relevant science
• from fragmented capacity to integrated ecosystem-building
• from low-cost manufacturing identity to innovation-driven healthcare power

That is why the scheme is important not only for health but also for industrial policy, science policy, and strategic economic positioning.

Conclusion

Biopharma SHAKTI is a major step toward repositioning India in the global pharmaceutical landscape. It aims to combine public health goals with scientific modernization and industrial upgrading. If implemented effectively, it can make India not just the pharmacy of the world for generics, but also a major global centre for affordable, advanced, and human-relevant biopharmaceutical innovation.

In the Budget 2025–26, the government introduced BioPharma SHAKTI Mission to boost domestic production of biologics and biosimilars and promote human-based (non-animal) testing methods, as animal models often fail to predict human response.